Related Experiment Video
Updated: Feb 21, 2026
Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
Published on: January 6, 2023
Time and Resource Implications of Subcutaneous Daratumumab-Based versus Intravenous Isatuximab-Based Treatment
Emma Smith1, Alessandro Camera2, Alex Bird3
1Johnson & Johnson, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4DP, UK. esmith92@its.jnj.com.
Introduction:
Multiple myeloma (MM) treatment is associated with significant healthcare provider (HCP) and patient time burden due to the frequency and duration of hospital visits for treatment. This study evaluated impacts on HCP and patient time burden of daratumumab subcutaneous (SC)-based versus isatuximab intravenous (IV)-based regimens in patients with newly diagnosed MM who are transplant ineligible.
Methods:
An online survey of HCPs (hemato-oncology specialists, nurse practitioners, and hospital pharmacists) was conducted in nine European countries and Egypt. Respondents provided estimates of HCP and patient time associated with individual SC and IV treatment steps. These survey data and published dosing schedules informed development of a resource utilization model to compare overall time burden for SC and IV regimens over a 2-year cumulative period.
Results:
HCPs reported savings in median active working time per treatment visit for steps before, during and after administration of daratumumab SC versus isatuximab IV treatments, with a total median saving of up to 135 min (39.1% reduction). HCPs also reported less median patient time per visit with daratumumab SC versus isatuximab IV treatments, with a total median saving of up to 115 min (27.1% reduction). Over 2 years, reduced time for SC versus IV administration, coupled with the less frequent dosing schedule for daratumumab versus isatuximab, resulted in marked time savings for HCPs and patients with D-Rd SC (HCPs: 221 h saved [64.2% reduction]; patients: 224 h [61.2% reduction]), D-VRd SC (HCPs: 157 h [45.6% reduction]; patients: 149 h [40.7% reduction]), and D-VMP SC (HCPs: 147 h [42.7% reduction]; patients: 140 h [38.3% reduction]) versus Isa-VRd IV.
Conclusions:
This study demonstrated notable time savings with daratumumab SC-based versus isatuximab IV-based regimens in patients with newly diagnosed MM who are transplant ineligible based on SC versus IV administration and less frequent daratumumab dosing.
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
